Effect of Lactobacillus DSM17938+ on Functional Constipation and Intestinal Flora in Pregnant Women

Last updated: January 25, 2025
Sponsor: Peking Union Medical College Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Constipation

Treatment

Lactulose oral solution treatment

Intervention with probiotic bacteria

Clinical Study ID

NCT06802042
K6993
  • Ages 18-40
  • Female

Study Summary

Constipation (constipation) is a common clinical symptom, including difficulty in defecation and / or reduced frequency of defecation, dry and hard stool, difficulty in defecation, feeling of inexhaustible defecation, feeling of anorectal obstruction, time-consuming defecation and need for auxiliary defecation. Reduced defecation means defecation less than 3 times a week.Constipation is very common during pregnancy, and studies have found that the incidence of constipation in pregnant women is as high as 40%. Among them, the prevalence of functional constipation in the early, middle, late and postpartum pregnancies is 35%, 39%, 21% and 17% respectively, with the highest in the early and middle pregnancies.Constipation can increase the psychological burden of pregnant women and affect their quality of life. Long-term severe constipation can also induce or aggravate hemorrhoids. Severe constipation can induce uterine contractions, which will adversely affect the pregnancy outcome of pregnant women.Studies have found that there is a difference in the abundance of intestinal flora between patients with constipation during pregnancy and pregnant women without digestive tract diseases.Although microecological preparations are not front-line drugs for the treatment of chronic constipation, they can promote intestinal peristalsis and the recovery of gastrointestinal motility by regulating the imbalance of intestinal flora. More and more researchers recommend them as long-term adjuvant drugs for chronic constipation. Probiotics are a type of microecological preparation, which refers to living microorganisms that can have beneficial health effects on the host after ingesting a sufficient amount.It is relatively safe to supplement probiotics during pregnancy.Our research team found a probiotic strain, Lactobacillus reuteri DSM17938+, which has no significant difference in improving constipation symptoms in patients with constipation compared with lactulose, and is even more effective than lactulose in alleviating abdominal pain and flatulence symptoms.However, clinical studies proving that Lactobacillus reuteri DSM17938 + is effective on constipation are generally concentrated abroad, and mainly focus on infants and young children, children, adults] or intestinal colic. Data on maternal population in China is lacking.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • (1) Pregnant women, age ≥18 years and <40 years old, and gestational age <28 weeks; (2) Must meet two or more of the following symptoms (Refer to the Roman IVstandard):

  • It is difficult to defecate at least 25% of the time;

  • It is lumpy or hard stool at least 25% of the time;

  • It is not enough to defecate at least 25% of the time;

  • It is at least 25% of the time that there is anorectalobstruction or obstruction in defecation;

  • It requires manual assistance at least 25% of the time; ⑥It is spontaneous defecation less than 3 times a week. Atthe same time, loose stools rarely occur when no laxativesare used, which does not meet the diagnostic criteria ofirritable bowel syndrome (IBS). The symptoms in the past 2weeks have met the above diagnostic criteria. (3) Pregnant women receive and follow high-protein andhigh-fiber dietary guidance during the first trimester. (4) There were no other complications. (5) No medicationwas used to interfere with constipation symptoms.

Exclusion

Exclusion Criteria:

  • (1) Non-pregnant women, age <18 years or ≥40 years old, and gestational age ≥28weeks; (2) Constipation caused by intestinal and systemic organic factors, drugs andother reasons, or concurrent with other non-constipation intestinal diseases; (3)History of use of antibiotics, probiotics, prebiotics, etc. in the past 2 weeks; (4)Pregnant women with thyroid disease, diabetes, hypertension, obesity, overweight orany metabolic disease.

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Lactulose oral solution treatment
Phase:
Study Start date:
January 09, 2025
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Chinese Academy of Medical Science & Peking Union Medical College Hospital

    Beijing, Beijing 100730
    China

    Active - Recruiting

  • Wenzhou People's Hospital

    Wenzhou, Zhejiang 325200
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.